5-chloro-6-fluoro-3-hydroxyquinolin-2(1H)-one | 1159706-41-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-chloro-6-fluoro-3-hydroxyquinolin-2(1H)-one
• 英文别名: 5-chloro-6-fluoro-3-hydroxy-1H-quinolin-2-one
• CAS: 1159706-41-8
• 化学式: C₉H₅ClFNO₂
• 分子量: 213.596
• InChiKey: SJNYFCFQCNCHDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  ethyl 5-chloro-6-fluoro-3-hydroxy-2-oxo-1,2-dihydroquinoline-4-carboxylate 在 lithium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 以9%的产率得到5-chloro-6-fluoro-3-hydroxyquinolin-2(1H)-one
  参考文献：
  名称：

  Discovery, SAR, and Pharmacokinetics of a Novel 3-Hydroxyquinolin-2(1H)-one Series of Potent d-Amino Acid Oxidase (DAAO) Inhibitors

  摘要：

  3-Hydroxyquinolin-2(1H)-one (2) was discovered by high throughput screening in a functional assay to be a potent inhibitor of human DAAO, and its binding affinity was confirmed in a Biacore assay. Cocrystallization of 2 with the human DAAO enzyme defined the binding site and guided the design of new analogues. The SAR, pharmacokinetics, brain exposure, and effects on cerebellum D-serine are described. Subsequent evaluation against the rat DAAO enzyme revealed a divergent SAR versus the human enzyme and may explain the high exposures of drug necessary to achieve significant changes in rat or mouse cerebellum D-serine.

  DOI：

  10.1021/jm900128w

文献信息

• METHODS TO TREAT DYSREGULATED BLOOD GLUCOSE DISORDERS
  申请人：REGENTS OF THE UNIVERSITY OF MINNESOTA

  公开号：US20150150836A1

  公开（公告）日：2015-06-04

  The invention provides methods and compositions for treating dysregulated blood glucose disorders.
• US9339482B2
  申请人：——

  公开号：US9339482B2

  公开（公告）日：2016-05-17
• US9468669B2
  申请人：——

  公开号：US9468669B2

  公开（公告）日：2016-10-18
• Discovery, SAR, and Pharmacokinetics of a Novel 3-Hydroxyquinolin-2(1<i>H</i>)-one Series of Potent <scp>d</scp>-Amino Acid Oxidase (DAAO) Inhibitors
  作者：Allen J. Duplantier、Stacey L. Becker、Michael J. Bohanon、Kris A. Borzilleri、Boris A. Chrunyk、James T. Downs、Lain-Yen Hu、Ayman El-Kattan、Larry C. James、Shenping Liu、Jiemin Lu、Noha Maklad、Mahmoud N. Mansour、Scot Mente、Mary A. Piotrowski、Subas M. Sakya、Susan Sheehan、Stefanus J. Steyn、Christine A. Strick、Victoria A. Williams、Lei Zhang

  DOI：10.1021/jm900128w

  日期：2009.6.11

  3-Hydroxyquinolin-2(1H)-one (2) was discovered by high throughput screening in a functional assay to be a potent inhibitor of human DAAO, and its binding affinity was confirmed in a Biacore assay. Cocrystallization of 2 with the human DAAO enzyme defined the binding site and guided the design of new analogues. The SAR, pharmacokinetics, brain exposure, and effects on cerebellum D-serine are described. Subsequent evaluation against the rat DAAO enzyme revealed a divergent SAR versus the human enzyme and may explain the high exposures of drug necessary to achieve significant changes in rat or mouse cerebellum D-serine.